Skip to main content

Table 1 Demographic and clinical characteristics of the participants in two groups

From: The relationship between severity of drug problems and perceived interdependence of drug use and sexual intercourse among adult males in drug addiction rehabilitation centers in Japan

  perceived interdependence of sexual intercourse and drug use   
weak groupa strong groupb Total Analysis
n = 143 n = 297 n = 440 Statistic p-value*
Age (median, Q1-Q3) 39 (32–46) 42 (36–48) 42 (34–47) U = 24,555.000 0.008
Heterosexual: n (%) 127 (88.8) 251 (84.5) 378 (85.9)   0.245
Completed high school: n (%) 67 (46.9) 126 (42.4) 193 (43.9)   0.412
Unemployed: n (%) 111 (77.6) 214 (72.1) 325 (73.9)   0.247
Living condition: n (%)
 Living in a dormitory (rehabilitation center) 117 (81.8) 222 (74.7) 339 (77.0)   0.116
 Daycare 11 (7.7) 30 (10.1) 41 (9.3)   0.486
 Undergoing training as rehabilitation staff 15 (10.5) 45 (15.2) 60 (13.6)   0.235
Chronic disease (physical disease): n (%) 22 (15.4) 74 (25.2) 96 (22.0)   0.026
Primary drug: n (%)
 Methamphetamine 56 (39.2) 214 (72.1) 270 (61.4)   < 0.001
 NPS 22 (15.4) 38 (12.8) 60 (13.6)   0.461
 Organic solvent 14 (9.8) 12 (4.0) 26 (5.9)   0.029
 Marijuana 11 (7.7) 13 (4.4) 24 (5.5)   0.179
 Prescription drugs 17 (11.9) 7 (2.4) 24 (5.5)   < 0.001
 Over-the-counter drugs 14 (9.8) 6 (2.0) 20 (4.5)   0.001
 Others (cocaine, heroin, MDMA, gas) 9 (6.3) 7 (2.4) 16 (3.6)   0.055
Drug-related criminal history: n (%) 40 (28.0) 163 (54.9) 203 (46.1)   < 0.001
Never experienced treatment: n (%) 22 (15.5) 64 (21.8) 86 (19.7)   0.157
Consistent condom use under the influence of drugs: n (%)
 Always uses condoms 66 (46.2) 38 (12.8) 104 (23.7)   < 0.001
 Sometimes a non-condom user 27 (18.9) 50 (16.9) 77 (17.5)   0.595
 Mostly a non-condom user 50 (35.0) 208 (70.3) 258 (58.8)   < 0.001
Injecting and sharing needles during drug use: n (%)
 None 74 (52.9) 60 (20.5) 134 (31.0)   < 0.001
 Only experienced injection 16 (11.4) 46 (15.8) 62 (14.4)   0.245
 Experienced injection and sharing needles 50 (35.7) 186 (63.7) 236 (54.6)   < 0.001
Diagnosis of sexually transmitted disease in lifetime: n (%)
 Hepatitis A 0 (0.0) 1 (0.3) 1 (0.2)   1.000
 Hepatitis B 1 (0.7) 18 (6.3) 19 (4.5)   0.006
 Hepatitis C 19 (13.6) 92 (32.2) 111 (26.1)   < 0.001
 Gonorrhea 6 (4.3) 30 (10.5) 36 (8.5)   0.040
 Chlamydia 7 (5.0) 22 (7.7) 29 (6.8)   0.413
 Syphilis 2 (1.4) 19 (6.6) 21 (4.9)   0.017
 HIV 0 (0.0) 18 (6.3) 18 (4.2)   0.001
 Never diagnosis of STD 110 (78.6) 139 (48.6) 249 (58.5)   < 0.001
DAST-20 total score (median, Q1-Q3) 13.0 (10–16) 15.0 (12–17) 14.0 (12–16) U = 25,873.500 < 0.001
  1. *p-value for Fisher’s exact test or Mann–Whitney U test
  2. Significant p-values are shown in bold type and underlined (p < 0.01)
  3. a Weak group consisted of respondents who considered the relationship between drug use and sexual intercourse was perceived “extremely weak + weak”
  4. b Strong group consisted of respondents who considered the relationship between drug use and sexual intercourse was perceived “extremely strong + strong”
  5. Abbreviations: NPS new psychoactive substances, MDMA 3, 4-methylenedioxymethamphetamine, STDs sexually transmitted diseases, HIV human immunodeficiency virus, DAST the Drug Abuse Screening Test